Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

These Analysts Cut Their Forecasts On Abbott After Q3 Results

Published 19/10/2023, 19:28
© Reuters These Analysts Cut Their Forecasts On Abbott After Q3 Results
ABT
-

Benzinga - by Lisa Levin, Benzinga Editor.

Abbott Laboratories (NYSE: ABT) reported better-than-expected third-quarter results.

Abbott reported quarterly adjusted EPS of $1.14, compared to $1.15 a year ago, beating the consensus of $1.04. Sales of $10.1 billion decreased 2.6%, beating the consensus of $9.32 billion.

Abbott said it sees FY23 adjusted EPS of $4.42-$4.46 versus prior guidance of $4.30-$4.50 and consensus of $4.18.

Abbott shares fell 0.1% to trade at $95.51 on Thursday.

These analysts made changes to their price targets on Abbott following earnings announcement.

  • Raymond James cut the price target on Abbott from $123 to $110. Raymond James analyst Jayson Bedford maintained an Outperform rating.
  • Wells Fargo lowered the price target on Abbott from $136 to $116. Wells Fargo analyst Lawrence Biegelsen maintained an Overweight rating.
  • Morgan Stanley slashed the price target on Abbott from $112 to $107. Morgan Stanley analyst David Lewis maintained an Equal-Weight rating.
Also Check This Out: Top 3 Financial Stocks You'll Regret Missing In Q4

Latest Ratings for ABT

DateFirmActionFromTo
Jan 2022Morgan StanleyMaintainsOverweight
Jan 2022Raymond JamesMaintainsOutperform
Jan 2022Morgan StanleyMaintainsOverweight
View More Analyst Ratings for ABT

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.